Integrated DNA Technologies (IDT) has introduced the Archer VARIANTPlex Lymphoma panel, a new tool for next-generation sequencing (NGS) to add to its existing portfolio of genomics solutions.
As stated in a press release from IDT, the panel is designed to help researchers detect genetic changes across 49 genes related to B-cell and T-cell lymphoma, including mutations, insertions, deletions, and variations in gene number.
Researchers can use the new panel independently, combine it with other Archer panels, or customize it for specific research needs. For more comprehensive blood cancer analysis, it can also be paired with IDT’s existing FUSIONPlex Lymphoma panel and the IMMUNOVerse BCR panel, the release states.
“The development of this panel was driven by our customers’ need for flexible and robust NGS solutions in the blood cancer research space,” said Verity Johnson, IDT vice president of Archer products, in the release. “IDT is committed to empowering our customers by providing the tools they need to accelerate the advancement of precision medicine.”
IDT’s Archer NGS solutions are flexible, allowing researchers to combine pre-designed panels and add targets through the Assay Marketplace or by working directly with an IDT design expert. The panels, which use Anchored Multiplex PCR chemistry, are compatible with a variety of sample types, including low-quality or older samples such as formalin-fixed, paraffin-embedded tissue.
The release notes that blood cancer affects about 1.2 million people globally each year. In recognition of Blood Cancer Awareness Month this September, IDT aims to renew its support for the research community by offering the the Archer VARIANTPlex panel to assist in combating lymphoma.
For more information on the Archer VARIANTPlex Lymphoma panel, interested parties can visit idtdna.com/VariantplexLymphomaAssay.
